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INTRODUCTION
Prosthesis-patient mismatch (PPM) can be considered after in-
sertion into the patient when the effective orifice area (EOA) is 
of the prosthesis valve and is less than that of a normal human 
valve, which results in an increased postoperative transvalvular 
gradient.1,2
Previous studies reported that PPM after aortic valve replace-
ment is associated with worse hemodynamics, decreased re-
gression of left ventricular (LV) hypertrophy, more cardiac 
events and higher mortality.3-6 However, PPM after mitral valve 
replacement (MVR) has not been widely investigated, and its 
incidence has been reported to vary.7-10 In addition, studies on 
the clinical impact of PPM following MVR on survival have 
shown conflicting results, although two recent trials showed 
that PPM in the mitral position independently affects long-
term survival.7,8 The most important reason for the discrepancy 
among the previous studies might be that the methods used to 
define PPM were different. Three different techniques have 
been used to calculate EOA, including the continuity equation 
(CE),7 pressure half time (PHT) method,10,11 and reference EOA 
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(EOAR).8,12-15 However, differences among the methods of cal-
culating PPM after MVR have not yet been clarified.
Dumesnil and Pibarot16 have addressed that indexed EOA 
derived from in vivo postoperative measures is the only param-
eter that can consistently be correlated with postoperative gra-
dients as well as clinical outcomes in defining PPM. Therefore, 
it is emphasized that the indexed EOA, not geometric specifica-
tions of the prosthesis, should be used to define PPM.17 Howev-
er, data showing correlation between indexed EOA from post-
operative echocardiography and clinical outcomes have been 
investigated mainly in patients with aortic prosthesis, and clini-
cal evidences supporting the use of calculated EOA using CE 
for defining PPM in mitral prosthesis are scarce.
We hypothesized that EOA derived from in vivo postopera-
tive measure using CE would be most valid compared with oth-
er parameters including PHT method and reference EOA for 
the evaluation of mitral PPM. Therefore, we investigated the in-
cidence of PPM in the mitral position using different methods 
of EOA determination, including calculation by CE, calculation 
by PHT and use of reference EOA, and compared them with 
various echocardiographic variables in patients with mitral ste-
nosis after MVR.
MATERIALS AND METHODS
Patient population
We retrospectively analyzed the data of patients who under-
went isolated MVR due to rheumatic mitral stenosis at Sever-
ance Cardiovascular Hospital from January 2004 to December 
2012. Patients with >2+ mitral valve regurgitation, >1+ aortic 
valve regurgitation and/or >mild aortic stenosis on preopera-
tive and postoperative echocardiography, and patients with 
cardiomyopathy or coronary artery disease requiring concur-
rent bypass surgery were excluded. This study was approved by 
the Institutional Review Board of Yonsei University, Severance 
Hospital, Seoul, Korea.
Echocardiographic measurement
Clinical and echocardiographic assessment was performed 
prior to MVR and 12–60 months after operation. The echocar-
diographic images of the included patients were reanalyzed by 
2 experienced echocardiographers who were unaware of the 
patient’s clinical data. LV internal diameter, septal thickness, 
and LV posterior wall thickness were measured at end-diastole. 
LV mass was calculated using the formula developed by De-
vereux, et al.,18 and LV mass was indexed for the body surface 
area. The left atrial volume was calculated from the parasternal 
long-axis view and apical four-chamber view using the prolate 
ellipse method19 and was indexed for the body surface area. 
The severity of tricuspid regurgitation (TR) was assessed using 
color flow imaging and regurgitant jet area.20 The calculated 
systolic pulmonary artery (PA) pressure was defined as: 4×(maxi-
mum velocity of TR jet)2+right atrial pressure. Right atrial pres-
sure was estimated by the inferior vena cava diameter and its 
response to inspiration.10,11 Doppler color flow mapping was 
used to assess the competency of the prosthetic valves.
EOA calculation and definition of PPM
Mitral valve EOA, calculated by CE (EOACE), was determined 
using the stroke volume measured in the LV outflow tract divid-
ed by the integral of the mitral valve trans-prosthetic velocity 
during diastole. Mitral valve EOA, calculated by PHT (EOAPHT), 
was calculated using the formula 220/PHT.21 Three cardiac cy-
cles for patients in sinus rhythm and five for patients in atrial fi-
brillation were recorded, and the results were averaged for ev-
ery patient. EOAR was determined from the literature or values 
offered by the manufacturer. EOACE, EOAPHT, and EOAR were in-
dexed for the body surface area (EOAICE, EOAIPHT, and EOAIR, 
respectively). Indexed EOA was used to define PPM as not sig-
nificant if >1.2 cm2/m2, moderate if >0.9 cm2/m2 and ≤1.2 cm2/
m2, and severe if ≤0.9 cm2/m2.7
Statistical analysis
The distributions of all relevant variables are reported as per-
centages or as mean±SD. The groups were compared using chi-
square statistics for categorical variables and Student’s t-test for 
continuous variables. Correlation between the variables was 
assessed with the Pearson correlation test. Intraclass correla-
tion coefficient (ICC) for a consistency was used to measure 
and compare agreement between EOACE and EOAPHT and be-
tween EOACE and EOAR. Good correlation was defined as an 
ICC >0.8. To determine independent predictors of postopera-
tive systolic PA pressure, linear relationships were checked with 
univariate linear regression analysis. Variables that had statisti-
cal significance in univariate analysis and EOA values were en-
tered in the multiple linear regression model. A p value <0.05 
was considered statistically significant.
RESULTS
Among the eligible 185 patients who underwent MVR due to 
mitral stenosis, 167 patients received postoperative echocar-
diography between 12 and 60 months after MVR. After exclud-
ing one patient who showed paravalvular leakage on postoper-
ative echocardiography, the remaining 166 patients (age 56±11 
years) with a median follow-up time of 16 months comprised 
the study population. Preoperative and postoperative variables 
of the studied populations are shown in Table 1. Of the 166 pa-
tients included in this study, there were 45 men and 121 wom-
en with a mean age of 56±11 years. Prevalence of hypertension 
and diabetes were 10% and 9%, respectively. Maze procedure 
and TV repair were performed in 42 (25%) and 66 (40%) pa-
tients, respectively, and atrial fibrillation during postoperative 
echocardiography was shown in 71 patients (43%).
http://dx.doi.org/10.3349/ymj.2016.57.2.328330
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Fig. 1 shows the prevalence of mitral valve PPM according to 
the methods used to calculate EOA. Prevalence ranged from 7% 
in PHT method to 49% in referred EOA method to 62% in CE 
method. There were 63 patients without PPM (38%), 80 patients 
with moderate PPM (48%) and 23 patients with severe PPM 
(14%), when EOAICE was used to define PPM. In contrast, the 
prevalence of moderate and severe PPM was relatively very low 
[8 patients (5%) and 3 patients (2%), respectively] according to 
EOAIPHT. There were 85 patients without PPM (51%), 73 patients 
with moderate PPM (44%) and 8 patients with severe PPM (5%) 
according to EOAIR.
Comparison of characteristics according to the method of 
PPM calculation is shown in Table 2. When PPM was defined 
by EOAICE, the prevalence of males was higher, body surface 
area was greater and trans-prosthetic pressure and postopera-
tive systolic PA pressure were higher in the PPM group. When 
PPM was defined by EOAIPHT, age at operation and prevalence 
of atrial fibrillation at follow-up were higher and left atrial vol-
ume index (LAVI) was larger in the PPM group. When we used 
EOAIR, prevalence of atrial fibrillation at follow-up and postop-
erative LV ejection fraction was higher in the PPM group. There 
were no significant differences in prevalence of moderate or 
greater TR at preoperative echocardiography between the 
groups in all three methods. However, there was a tendency of 
high occurrence of moderate or greater TR at postoperative 
echocardiography in PPM group, only when PPM was defined 
according to CE (p=0.069).
Correlations between EOAICE and EOAIPHT, between EOAICE 
and EOAIR, and between EOAIPHT and EOAIR are demonstrated 
in Fig. 2. All the agreements between EOAICE and EOAIPHT, be-
tween EOAICE and EOAIR, and between EOAIPHT and EOAIR were 
poor [0.430, 95% confidence interval (CI) 0.226–0.580; 0.320, 
Table 1. Characteristics of the Studied Population
Variable Value (n=166)
Age at operation (yrs) 56±11
Gender 
Female 121 (73%)
Male 45 (27%)
Body surface area (m2) 1.58±0.25
Hypertension 17 (10%)
Diabetes mellitus 15 (9%)
Preoperative atrial fibrillation 102 (61%)
Maze procedure 42 (25%)
Tricuspid valve repair 66 (40%)
Atrial fibrillation at follow-up 71 (43%)
Type of prosthesis
Mechanical prosthesis 129 (78%)
Bioprosthesis 37 (22%)
Prosthesis implanted
St. Jude Mechanical 64 (39%)
ATS 29 (17%)
On-X 25 (15%)
Carpentier Edwards Perimount 16 (10%)
St. Jude Medical Epic 12 (7%)
St. Jude Medical Biocor 7 (4%)
Edwards MIRA 7 (4%)
SORIN 4 (2%)
Hancock II  2 (1%)
Prosthesis size (mm)
25 22 (13%)
27 76 (46%)
29 62 (37%)
31 6 (4%)
MV EOAR (cm2) 2.0±0.5
MV EOAIR (cm2/m2) 1.3±0.3
Preoperative hemodynamics
Systolic blood pressure, mm Hg 117±15
Diastolic blood pressure, mm Hg 74±10
Heart rate, bpm 73±16
Preoperative echocardiography
LVEF (%) 62±9
LVMI (g/m2) 90±21
LAVI (mL/m2) 92±47
TR grade≥moderate 50 (33%)
Systolic PA pressure (mm Hg) 41±14
Mitral valve area by 2-dimensional planimetry (cm2) 0.9±0.2
Postoperative hemodynamics
Systolic blood pressure, mm Hg 119±15
Diastolic blood pressure, mm Hg 74±11
Heart rate, bpm 71±11
Postoperative echocardiography
LVEF (%) 64±6
LVMI (g/m2) 113±28
LAVI (mL/m2) 60±33
Table 1. Characteristics of the Studied Population (Continued)
Variable Value (n=166)
TR grade≥moderate 17 (10%)
Systolic PA pressure (mm Hg) 27±7
Mean diastolic trans-prosthetic gradient (mm Hg) 3.5±1.2
MV EOACE (cm2) 1.8±0.5
MV EOAPHT (cm2) 2.6±0.5
MV EOAICE (cm2/m2) 1.2±0.3
MV EOAIPHT (cm2/m2) 1.7±0.4
MV, mitral valve; EOAR, referred effective orifice area; EOAIR, referred effec-
tive orifice area index; LVEF, left ventricular ejection fraction; LVMI, left ven-
tricular mass index; LAVI, left atrial volume index; TR, tricuspid regurgitation; 
PA, pulmonary artery; 2D, 2-dimensional; EOACE, measured effective orifice 
area by continuity equation; EOAICE, measured effective orifice area index by 
continuity equation; EOAPHT, measured effective orifice area by pressure half 
time; EOAIPHT, measured effective orifice area index by pressure half time.
St. Jude Mechanical (St. Jude Medical, Minneapolis, MN, USA); ATS (ATS 
Medical, Minneapolis, MN, USA); On-X (MCRI, Austin, TX, USA); Carpentier 
Edwards Perimount (Edwards Lifesciences, Irvine, CA, USA); St. Jude Medi-
cal Epic (St. Jude Medical, Minneapolis, MN, USA); St. Jude Medical Biocor 
(St. Jude Medical, Minneapolis, MN, USA); Edwards MIRA (Edwards Life-
sciences, Irvine, CA, USA); SORIN (SORIN-Biomedica, Saluggia, Italy); Han-
cock II (Medtronic, Inc., Minneapolis, MN, USA).
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95% CI 0.077–0.500; and 0.362, 95% CI 0.133–0.530, respective-
ly]. When the patients were divided into two groups according 
to the presence of PPM using various methods, the results of 
correlation were similar. CE methods poorly correlated with re-
ferred method (ICC=0.249) and PHT method (ICC=0.228) in 
defining PPM. Correlation between referred and PHT method 
was also poor (ICC=0.306).
Fig. 3 shows the correlation between indexed EOAs and post-
operative systolic PA pressure. Among the indexed EOAs, EO-
AICE showed significant correlation with postoperative systolic 
PA pressure (r=-0.384, p<0.001). In contrast, there were no sig-
nificant correlations between EOAIPHT and postoperative sys-
tolic PA pressure (r=-0.089, p=0.254) or between EOAIR and 
postoperative systolic PA pressure (r=-0.110, p=0.158). Linear 
regression analysis was performed to identify the predictors of 
postoperative systolic PA pressure as a dependent variable (Ta-
ble 2). On multivariate regression, age, mitral valve EOAICE, and 
postoperative LAVI were found to be independent predictor of 
postoperative systolic PA pressure (p=0.002, p<0.001, and 
p=0.001, respectively) (Table 3). On the contrary, EOAIPHT and 
EOAIR were not predictors for postoperative systolic PA pres-
sure.
Fig. 4 compares of postoperative systolic PA pressure among 
the patients without PPM (n=63), with moderate PPM (n=80) 
and with severe PPM (n=23) according to EOAICE. Systolic PA 
pressure was statistically different between the patients without 
PPM and with moderate PPM (25±6 mm Hg vs. 28±6 mm Hg, 
p=0.007), as well as between patients with moderate and severe 
PPM (28±6 mm Hg vs. 33±11 mm Hg, p=0.037).
DISCUSSION
The principal findings of the present study are that 1) the inci-
dence of PPM after MVR in patients with mitral stenosis was 
variable according to the different methods of determining 
EOA, and 2) among the EOAs assessed by 3 different methods, 
including the CE method, PHT method and use of reference 
values, only the EOAICE was found to be independently associ-
ated with the postoperative systolic PA pressure.
Conflicting data on PPM after MVR
Since first described in 1978,1 PPM after MVR has been sug-
gested to correlate with poor clinical outcomes including per-
sistent pulmonary hypertension and late functional TR.4,9 How-
ever, some authors have insisted that PPM did not affect survival 
after MVR,10,15 although several recent trials suggested that mi-
tral PPM independently affects long-term survival.7,8 In addi-
tion, the overall incidence of PPM (<1.3 to <1.2 cm2/m2) after 
MVR has been shown to vary, ranging from 3.7% to 85.9%.7,8,10-15 
The incidence of moderate PPM has also been reported to vary, 
ranging from 37.4% to 69.5%, and the incidence of severe PPM 
ranged from 8.7% to 16.4%.22
Explanations for discrepancy
There may be several explanations concerning the conflicting 
data on the clinical effect of PPM after MVR. First, different 
valve types and patients groups were employed in the studies. 
Especially, patients suffering PPM have sometimes additional 
risk factors, including hypertension and diabetes, which could 
also affect long-term survival. Second, when evaluating the im-
pact of PPM after MVR, it is also important to consider patho-
physiological status of patients. In the current study, minimize 
those problems, we included only patients with rheumatic mi-
tral stenosis and analyzed postoperative echocardiography 12 
to 60 months after MVR, thus avoiding dynamic changes of he-
modynamic status at early postoperative period and the late 
development of prosthetic valve malfunction which might be 
EOAIR
Fig. 1. Prevalence of PPM according to the methods used to calculate effective orifice area. PPM, prosthesis-patient mismatch; EOAICE, measured effec-
tive orifice area index by continuity equation; EOAIPHT, measured effective orifice area index by pressure half time; EOAIR, referred effective orifice area index.
No PPM Moderate PPM Severe PPM
EOAICE
23 (14%)
80 (48%)63 (38%)
Prevalence of PPM
EOAIPHT
8 (5%) 3 (2%)
155 (93%)
8 (5%)
85 (51%) 73 (44%)
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associated with pannus formation. Consequently, we found 
that PPM determined by CE showed significant correlation 
with various postoperative hemodynamic parameters.
Methods to determine effective orifice area 
The most important reason for discrepancy among the previ-
ous studies might be that the methods used to define PPM were 
different. In previous studies, three different methods have 
Table 2. Characteristics of the Study Population According to the Method of Prosthesis-Patient Mismatch Determination
Variable
EOACE EOAPHT EOAR
No PPM 
(n=63)
PPM 
(n=103)
p value
No PPM 
(n=155)
PPM 
(n=11)
p value
No PPM 
(n=85)
PPM 
(n=81)
p value
Age at operation (yrs) 56±11 56±11 0.810 56±11 64±9 0.016 55±11 57±11 0.211
Gender 0.048 0.475 0.108
Female 51 (81%) 70 (68%) 114 (74%) 7 (64%) 66 (78%) 55 (68%)
Male 12 (19%) 33 (32%) 41 (26%) 4 (36%) 19 (22%) 26 (32%)
Body surface area (m2) 1.53±0.15 1.60±0.14 0.001 1.57±0.15 1.63±0.15 0.209 1.55±0.15 1.61±0.14 0.211
Hypertension 6 (10%) 11 (11%) 0.517 13 (8%) 4 (36%) 0.016 8 (9%) 9 (11%) 0.718
Diabetes mellitus 5 (8%) 10 (10%) 0.465 14 (9%) 1 (6%) 0.659 7 (8%) 8 (10%) 0.712
Preoperative atrial fibrillation 40 (63%) 62 (60%) 0.399 91 (59%) 11 (100%) 0.004 45 (54%) 57 (70%) 0.021
Maze procedure 19 (30%) 23 (22%) 0.895 41 (26%) 1 (6%) 0.090 23 (27%) 19 (23%) 0.130
Tricuspid valve repair 27 (43%) 39 (38%) 0.524 61 (39%) 5 (45%) 0.690 29 (34%) 37 (46%) 0.128
Atrial fibrillation at follow-up 26 (41%) 45 (44%) 0.443 62 (40%) 9 (82%) 0.007 29 (34%) 42 (52%) 0.016
Type of prosthesis 0.242 0.001 0.008
Mechanical prosthesis 52 (83%) 77 (75%) 125 (81%) 4 (36%) 73 (86%) 56 (69%)
Bioprosthesis 11 (17%) 26 (25%) 30 (19%) 7 (64%) 12 (14%) 25 (31%)
Prosthesis size (mm) 0.484 0.307 0.356
25 6 (10%) 16 (16%) 21 (14%) 1 (9%) 8 (9%) 14 (17%)
27 27 (43%) 49 (48%) 68 (44%) 8 (73%) 38 (45%) 38 (47%)
29 27 (43%) 35 (34%) 60 (34%) 2 (18%) 35 (41%) 37 (46%)
31 3 (5%) 3 (5%) 6 (4%) 0 (0%) 4 (5%) 2 (2%)
Mitral valve EOAR (cm2) 2.1±0.5 2.0±0.5 0.339 2.1±0.5 1.7±0.3 0.016 2.4±0.5 1.6±0.2 <0.001
Mitral valve EOAIR (cm2/m2) 1.4±0.4 1.3±0.3 0.034 1.3±0.3 1.0±0.2 0.004 1.6±0.3 1.0±0.1 <0.001
Preoperative echocardiography
LVEF (%) 62±9 62±9 0.762 64±6 62±5 0.389 62±8 62±9 0.585
LVMI (g/m2) 87±23 92±20 0.145 89±20 113±21 0.122 91±22 89±20 0.585
LAVI (mL/m2) 110±31 114±26 0.444 89±43 135±71 0.057 92±43 93±50 0.868
TR grade≥moderate 22 (35%) 28 (27%) 0.292 48 (31%) 2 (18%) 0.372 25 (29%) 25 (31%) 0.838
Systolic PA pressure (mm Hg) 43±14 40±14 0.169 41±14 40±9 0.832 39±11 43±16 0.051
Mitral valve area by 2D planimetry (cm2) 0.9±0.2 0.9±0.2 0.236 0.9±0.2 0.8±0.2 0.158 0.9±0.2 0.9±0.2 0.264
Postoperative echocardiography
LVEF (%) 64±6 63±6 0.245 64±6 62±5 0.389 62±6 65±6 0.013
LVMI (g/m2) 103±56 86±39 0.131 111±27 131±39 0.122 114±29 112±27 0.626
LAVI (mL/m2) 66±42 57±24 0.089 59±31 85±43 0.008 58±30 63±35 0.380
TR grade≥moderate 3 (5%) 14 (14%) 0.069 15 (10%) 2 (18%) 0.369 9 (11%) 8 (10%) 0.880
Mean diastolic trans-prosthetic 
   gradient (mm Hg)
3.2±1.1 3.7±1.2 0.021 3.4±1.2 3.4±1.5 0.844 3.4±1.3 3.4±1.0 0.915
Systolic PA pressure (mm Hg) 25±6 29±8 0.001 27±7 29±9 0.381 27±7 28±8 0.440
MV EOACE (cm2) 2.2±0.4 1.6±0.2 <0.001 1.8±0.5 1.6±0.3 0.120 1.8±0.5 1.8±0.5 0.520
MV EOAPHT (cm2) 2.8±0.5 2.6±0.5 0.014 2.7±0.4 1.7±0.3 <0.001 2.7±0.5 2.6±0.5 0.114
MV EOAICE (cm2/m2) 1.5±0.2 1.0±0.1 <0.001 1.2±0.3 1.0±0.2 0.029 1.2±0.3 1.1±0.3 0.093
MV EOAIPHT (cm2/m2) 1.8±0.4 1.6±0.3 <0.001 1.8±0.3 1.1±0.2 <0.001 1.8±0.4 1.6±0.3 0.007
MV, mitral valve; EOAR, referred effective orifice area; EOAIR, referred effective orifice area index; LVEF, left ventricular ejection fraction; LVMI, left ventricular 
mass index; LAVI, left atrial volume index; TR, tricuspid regurgitation; PA, pulmonary artery; 2D, 2-dimensional; EOACE, measured effective orifice area by conti-
nuity equation; EOAICE, measured effective orifice area index by continuity equation; EOAPHT, measured effective orifice area by pressure half time; EOAIPHT, mea-
sured effective orifice area index by pressure half time.
333http://dx.doi.org/10.3349/ymj.2016.57.2.328
In-Jeong Cho, et al.
been used to calculate EOA, including the CE method,7 PHT 
method,10,11 and reference EOA.8,12-15
We compared the three methods and found that agreement 
among EOAICE, EOAIPHT, and EOAR was poor, and the preva-
lence of PPM varied according to the calculation method, rang-
ing from 7% in the PHT method to 49% in the reference EOA 
method to 62% in the CE method. This finding explains the dis-
crepant prevalence of PPM and conflicting data about the prog-
nosis of PPM in the various studies. Long-term survival data of 
patients with PPM defined by EOACE has not yet been reported, 
and further studies with EOACE might be necessary to clarify the 
clinical impact of PPM.
Interestingly, it has been reported in the previous reports9,23 
that prevalence of PPM was relatively high when CE was used 
to define PPM , ranging from 42% to 71%. We also found similar 
results of high prevalence of PPM, especially in moderate PPM. 
Possible explanation is that in bileaflet valves, the smaller cen-
tral orifice has a higher velocity than the larger outside orifice, 
which may lead to underestimation of EOACE.17 Patients who 
underwent MVR with bileaflet mechanical heart valve were 
78% in the current study, and therefore, there is a chance that 
EOACE might be underestimated in part. Therefore, further re-
search and overall agreement are required to establish the al-
lowable range of EOACE for the definition of PPM, although CE 
methods might be the most appropriate method to determine 
EOA. In addition, clinical implication of moderate PPM in mi-
tral position is not clear, since moderate PPM did not show sta-
tistically significant result of poor survival, contrast to severe 
PPM, which showed poor long-term survival.7 Nevertheless, we 
demonstrated that even patients with moderate PPM showed 
raised systolic PA pressure compared to those without PPM, 
suggesting clinical significance of moderate PPM. Therefore, 
the clinical impact of moderate PPM and EOA range for the di-
agnosis of PPM might need further investigation.
Among the three methods, mentioned above EOAPHT is not 
recommended for calculating EOA of the mitral prosthesis be-
cause of the influence of chronotropic conditions and atrioven-
tricular compliance.24 Nevertheless, some studies still use PHT 
method to define EOA.10,11 In the current study, as anticipated, 
EOA calculation via the PHT method was found to be not asso-
ciated with postoperative hemodynamic parameters and large-
ly overestimated the EOA compared to other methods. There-
fore, we should try not to use PHT to calculate EOA in mitral 
prosthesis.
Pulmonary artery pressure after MVR
A rise in PA pressure can result from elevation of pulmonary 
blood flow, pulmonary venous pressure and/or vascular resis-
Fig. 2. Correlation between EOAICE and EOAIPHT (A), between EOAICE and EOAIR (B) and between EOAIPHT and EOAIR (C). EOAICE, measured effective orifice 
area index by continuity equation; EOAIPHT, measured effective orifice area index by pressure half time; EOAIR, referred effective orifice area index. 
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tance,9 and pulmonary hypertension is an important risk factor 
for morbidity and mortality in patients with various cardiovas-
cular diseases.25-27 Pulmonary hypertension is frequently ob-
served in patients with mitral stenosis. Since increased PA pres-
sure is associated with poor functional capacity and a dismal 
prognosis in patients with severe mitral valve disease, normal-
ization of PA pressure constitutes a crucial goal of MVR.28-30
The development of late TR after MVR is an important com-
plication of the surgery, since it is associated with a severe im-
pairment of exercise capacity and a poor symptomatic out-
comes.31 However, the pathogenesis of this condition remains 
poorly understood, and treatment for the patients with late TR 
is clinically difficult to decide. Recently, it has been reported 
that mitral PPM is associated with the persistence of TR and 
pulmonary hypertension following MVR.23 Our study also dem-
onstrated similar results, showing a tendency of high preva-
lence in moderate or greater TR in PPM group, defined by CE. 
In addition, PPM calculated by EOAICE showed higher trans-
prosthetic pressure, and EOAICE was the only parameter which 
showed independent correlation with postoperative systolic PA 
pressure. Systolic PA pressure has been known to be influenced 
by many factors including age, diastolic dysfunction and car-
diopulmonary disease,32 as well as trans-prosthetic pressure. 
Since we enrolled homogenous, relatively young patient popu-
lation of pure mitral stenosis, we can speculate that systolic PA 
pressure might be influenced mainly by trans-prosthetic gradi-
ent in the studied population. Therefore, the use of EOAICE 
rather than EOAIPHT and EOAIR may be appropriate for identify-
ing PPM in the mitral position, since hemodynamic variables, 
including trans-prosthetic pressure and systolic PA pressure, 
showed significant correlation with EOA, only when it is calcu-
lated by using CE.
Unfortunately, however, most previous studies on PPM after 
MVR used EOAIR to define PPM. EOAICE was used to define 
PPM in only two studies, and both demonstrated clinical signif-
icance of PPM after MVR, including association with persistent 
pulmonary hypertension and late TR.9,23 Therefore, further larg-
er studies to define PPM using EOAICE are needed to clarify 
clinical significance and implications of PPM after MVR.
Limitations
The results of the study were based on retrospective analysis; 
however, we carefully reviewed patient medical records and 
echocardiography. As our findings are based upon an observa-
tional cohort of patients with rheumatic mitral stenosis, they 
may not necessarily be generalizable to all patients with mitral 
regurgitation. We compared indexed EOA to systolic PA pres-
sure, not clinical outcome, since the studied group was at rela-
tively low risk for cardiovascular events, as indicated by the low 
prevalence of combined co-morbidities such as hypertension 
and diabetes. In addition, functional data, such as maximum 
exercise capacity and maximum oxygen consumption, which 
would be more helpful for identifying the clinical implication of 
mitral PPM, were not included. Prevalence of pulmonary hy-
pertension (systolic PA pressure >40 mm Hg) was relatively low, 
and therefore, further investigation into the clinical significance 
of the results of the current study is needed. Patients with atrial 
fibrillation were included in the study population, although 
five cardiac cycles were recorded and these results were aver-
aged. We used linear regression analysis to determine indepen-
dent predictors of systolic PA pressure, although we cannot 
conclude that there is no association just because the linear re-
Table 3. Multivariate Regression Analysis for the Predictors of Systolic 
PA Pressure after Mitral Valve Replacement
Variable β coefficient 95% CI p value
Model 1
Age at operation 0.23 0.06 to 0.26 0.002
Preoperative systolic PA pressure 0.09 -0.02 to 0.12 0.179
Postoperative LAVI 0.25 0.02 to 0.09 0.001
Mitral valve EOAICE -0.37 -12.2 to -5.8 <0.001
Model 2 
Age at operation 0.28 0.08 to 0.30 0.001
Preoperative systolic PA pressure 0.07 -0.04 to 0.11 0.324
Postoperative LAVI 0.23 0.02 to 0.09 0.006
Mitral valve EOAIPHT -0.04 -3.68 to 1.95 0.543
Model 3
Age at operation 0.27 0.07 to 0.29 0.001
Preoperative systolic PA pressure 0.06 -0.04 to 0.11 0.402
Postoperative LAVI 0.23 0.02 to 0.09 0.004
Mitral valve EOAIR -0.05 -4.28 to 2.00 0.474
CI, confidence interval; PA, pulmonary artery; EOAICE, measured effective ori-
fice area index by continuity equation; LAVI, left atrial volume index; EOAIPHT, 
measured effective orifice area index by pressure half time; EOAIR, referred 
effective orifice area index.
Fig. 4. Comparison of postoperative systolic PA pressure among patients 
without PPM (n=63) to those with moderate PPM (n=80) and with severe 
PPM (n=23), defined using the continuity equation. Vertical bars represent 
range, boxes represent inter-quartile range, and horizontal lines represent 
the median. PPM, prosthesis-patient mismatch; PA, pulmonary artery.
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gression is not significant. Nevertheless, the association with 
EOAIPHT and EOAIR is unlikely, since there were no significant 
differences in systolic PA pressure between the groups, and the 
multivariate regression analysis showed that EOAIPHT and EO-
AIR were not predictors of systolic PA pressure.
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